Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of “Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned a consensus rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $41.20.

A number of brokerages have recently commented on BCAX. Wedbush reissued an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. HC Wainwright raised their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Rodman & Renshaw began coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company.

Institutional Investors Weigh In On Bicara Therapeutics

Several large investors have recently added to or reduced their stakes in BCAX. First Turn Management LLC bought a new position in shares of Bicara Therapeutics during the third quarter worth about $14,324,000. Geode Capital Management LLC bought a new stake in shares of Bicara Therapeutics during the third quarter valued at approximately $1,239,000. Vestal Point Capital LP acquired a new position in shares of Bicara Therapeutics during the third quarter worth approximately $10,825,000. FMR LLC acquired a new position in shares of Bicara Therapeutics during the third quarter worth approximately $57,913,000. Finally, Braidwell LP bought a new position in Bicara Therapeutics in the 3rd quarter worth approximately $42,219,000.

Bicara Therapeutics Stock Performance

Shares of Bicara Therapeutics stock opened at $13.82 on Friday. The firm has a fifty day moving average price of $14.49. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.